Qiagen N.V.

DB:QIA Stock Report

Market Cap: €9.0b

Qiagen Valuation

Is QIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of QIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: QIA (€41.01) is trading below our estimate of fair value (€63.29)

Significantly Below Fair Value: QIA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for QIA?

Key metric: As QIA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for QIA. This is calculated by dividing QIA's market cap by their current earnings.
What is QIA's PE Ratio?
PE Ratio102.3x
EarningsUS$92.93m
Market CapUS$9.41b

Price to Earnings Ratio vs Peers

How does QIA's PE Ratio compare to its peers?

The above table shows the PE ratio for QIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average66.3x
SRT3 Sartorius
188.8x36.4%€13.4b
1SXP SCHOTT Pharma KGaA
26.7x15.9%€4.0b
GXI Gerresheimer
22.3x21.7%€2.6b
ERF Eurofins Scientific
27.3x18.3%€8.9b
QIA Qiagen
102.3x34.4%€9.4b

Price-To-Earnings vs Peers: QIA is expensive based on its Price-To-Earnings Ratio (102.3x) compared to the peer average (66.3x).

Price to Earnings Ratio vs Industry

How does QIA's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
QIA 102.3xIndustry Avg. 37.1xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: QIA is expensive based on its Price-To-Earnings Ratio (102.3x) compared to the European Life Sciences industry average (37.4x).

Price to Earnings Ratio vs Fair Ratio

What is QIA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

QIA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio102.3x
Fair PE Ratio25.9x

Price-To-Earnings vs Fair Ratio: QIA is expensive based on its Price-To-Earnings Ratio (102.3x) compared to the estimated Fair Price-To-Earnings Ratio (25.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst QIA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€41.01
€48.00
+17.0%
8.0%€56.93€40.32n/a17
Nov ’25€39.57
€46.68
+18.0%
7.8%€55.41€40.46n/a17
Oct ’25€40.43
€46.17
+14.2%
7.8%€54.34€39.68n/a17
Sep ’25€41.70
€46.52
+11.6%
7.8%€54.76€39.99n/a17
Aug ’25€42.18
€46.80
+11.0%
8.4%€55.60€40.60n/a17
Jul ’25€37.75
€47.41
+25.6%
9.0%€57.80€40.94n/a17
Jun ’25€39.24
€46.55
+18.6%
9.3%€56.89€40.30n/a16
May ’25€38.68
€47.25
+22.2%
9.5%€57.85€39.75n/a16
Apr ’25€39.50
€47.66
+20.7%
8.9%€57.32€39.38n/a16
Mar ’25€39.45
€47.42
+20.2%
8.9%€57.03€39.19n/a16
Feb ’25€40.14
€47.71
+18.9%
9.3%€57.05€40.41n/a16
Jan ’25€40.53
€46.16
+13.9%
10.1%€56.35€39.45n/a17
Dec ’24€38.70
€45.79
+18.3%
10.6%€56.68€39.68n/a16
Nov ’24€36.47
€48.03
+31.7%
11.8%€58.53€40.97€39.5715
Oct ’24€39.28
€51.00
+29.8%
8.8%€58.51€41.44€40.4315
Sep ’24€42.92
€49.98
+16.5%
10.2%€60.48€40.16€41.7014
Aug ’24€44.16
€49.74
+12.6%
10.4%€59.31€39.38€42.1814
Jul ’24€42.60
€51.18
+20.1%
10.4%€60.94€40.47€37.7514
Jun ’24€43.93
€51.92
+18.2%
10.3%€61.32€40.72€39.2413
May ’24€41.43
€52.45
+26.6%
8.1%€58.26€44.17€38.6811
Apr ’24€42.99
€53.45
+24.3%
10.4%€60.57€41.52€39.5012
Mar ’24€44.23
€52.46
+18.6%
10.2%€59.54€40.81€39.4512
Feb ’24€46.27
€51.31
+10.9%
9.7%€59.41€40.73€40.1412
Jan ’24€48.43
€54.44
+12.4%
9.2%€63.85€43.77€40.5311
Dec ’23€49.33
€54.44
+10.4%
9.2%€63.85€43.77€38.7011
Nov ’23€46.37
€57.71
+24.5%
10.7%€65.87€45.16€36.4711

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

7D

-4.3%

1Y

91.5%

Teva Pharmaceutical Industries

US$19.4b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEV

US$16.25

7D

2.5%

1Y

89.8%

Merck

US$252.6b

Operates as a healthcare company worldwide.

6MK

US$97.10

7D

6.7%

1Y

3.9%